Literature DB >> 29561328

Multiple Sclerosis: B Cells Take Center Stage.

Anne-Katrin Pröbstel1, Stephen L Hauser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29561328      PMCID： PMC6505460          DOI： 10.1097/WNO.0000000000000642

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN： 1070-8022            Impact factor:   3.042


× No keyword cloud information.
  77 in total

Review 1.  Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

Authors:  H-Christian von Büdingen; Arumugam Palanichamy; Klaus Lehmann-Horn; Brady A Michel; Scott S Zamvil
Journal:  Eur Neurol       Date:  2015-03-25       Impact factor: 1.710

2.  Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.

Authors:  Y Joy Yu; Yin Zhang; Margaret Kenrick; Kwame Hoyte; Wilman Luk; Yanmei Lu; Jasvinder Atwal; J Michael Elliott; Saileta Prabhu; Ryan J Watts; Mark S Dennis
Journal:  Sci Transl Med       Date:  2011-05-25       Impact factor: 17.956

3.  Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

Authors:  Sabine Cepok; Berit Rosche; Verena Grummel; Friederike Vogel; Dun Zhou; Joachim Sayn; Norbert Sommer; Hans-Peter Hartung; Bernhard Hemmer
Journal:  Brain       Date:  2005-03-30       Impact factor: 13.501

4.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

5.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

6.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.

Authors:  Kerstin Berer; Lisa Ann Gerdes; Egle Cekanaviciute; Xiaoming Jia; Liang Xiao; Zhongkui Xia; Chuan Liu; Luisa Klotz; Uta Stauffer; Sergio E Baranzini; Tania Kümpfel; Reinhard Hohlfeld; Gurumoorthy Krishnamoorthy; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-11       Impact factor: 11.205

8.  Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

Authors:  Jessica A Couch; Y Joy Yu; Yin Zhang; Jacqueline M Tarrant; Reina N Fuji; William J Meilandt; Hilda Solanoy; Raymond K Tong; Kwame Hoyte; Wilman Luk; Yanmei Lu; Kapil Gadkar; Saileta Prabhu; Benjamin A Ordonia; Quyen Nguyen; Yuwen Lin; Zhonghua Lin; Mercedesz Balazs; Kimberly Scearce-Levie; James A Ernst; Mark S Dennis; Ryan J Watts
Journal:  Sci Transl Med       Date:  2013-05-01       Impact factor: 17.956

9.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

Authors:  Roberta Magliozzi; Owain Howell; Abhilash Vora; Barbara Serafini; Richard Nicholas; Maria Puopolo; Richard Reynolds; Francesca Aloisi
Journal:  Brain       Date:  2007-04       Impact factor: 13.501

10.  MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.

Authors:  Nicolas Molnarfi; Ulf Schulze-Topphoff; Martin S Weber; Juan C Patarroyo; Thomas Prod'homme; Michel Varrin-Doyer; Aparna Shetty; Christopher Linington; Anthony J Slavin; Juan Hidalgo; Dieter E Jenne; Hartmut Wekerle; Raymond A Sobel; Claude C A Bernard; Mark J Shlomchik; Scott S Zamvil
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307
View more
  4 in total

1.  Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.

Authors:  Marina Boziki; Christos Bakirtzis; Styliani-Aggeliki Sintila; Evangelia Kesidou; Evdoxia Gounari; Aliki Ioakimidou; Vasiliki Tsavdaridou; Lemonia Skoura; Asimina Fylaktou; Vasiliki Nikolaidou; Maria Stangou; Ioannis Nikolaidis; Virginia Giantzi; Eleni Karafoulidou; Paschalis Theotokis; Nikolaos Grigoriadis
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

2.  Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.

Authors:  Samuel Alsén; Jakob Cervin; Yaxiong Deng; Louis Szeponik; Ulf Alexander Wenzel; Joakim Karlsson; Helena Cucak; Megan Livingston; David Bryder; Qianjin Lu; Bengt Johansson-Lindbom; Ulf Yrlid
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561

3.  Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.

Authors:  Julia Baguña Torres; Jay Roodselaar; Megan Sealey; Marina Ziehn; Marc Bigaud; Rainer Kneuer; David Leppert; Gisbert Weckbecker; Bart Cornelissen; Daniel C Anthony
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

Review 4.  Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis.

Authors:  Meng-Ge Yang; Li Sun; Jinming Han; Chao Zheng; Hudong Liang; Jie Zhu; Tao Jin
Journal:  Mol Brain       Date:  2019-12-27       Impact factor: 4.041
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.